NEO

MKT CAP:$215M

NeoGenomics, Inc.

Market Cap

$215M

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$8.14-$3.62 (-30.80%)

Apr 21, 2026

Company Details

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, refer...

CEO

Anthony Zook

IPO Date

Mar 16, 2004

Website

www.neogenomics.com

Key Metrics TTM

Revenue

$727M

+10.1% YoY

Net Income

-$108M

EPS (Diluted)

-$4.18

Free Cash Flow

-$22M

Revenue / Share

$28.27

Gross Margin

42.2%

Operating Margin

-15.6%

Net Margin

-14.9%

FCF Margin

-3.0%

P/S

0.3x

P/E

—

Earnings Reports

Q1 2026

Apr 28, 2026

PENDING

FY 2025

Feb 17, 2026

$727M+10.1%EPS -$4.20

Q4 2025

Feb 17, 2026

$190M+10.6%EPS -$0.38

Q3 2025

Oct 28, 2025

$188M+11.9%EPS -$1.05

Q2 2025

Jul 29, 2025

$181M+10.2%EPS -$1.75

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$117M	$38M	-$52M
Q2 22	$125M	$44M	-$40M
Q3 22	$129M	$49M	-$40M
Q4 22	$139M	$57M	-$26M
Q1 23	$137M	$55M	-$35M
Q2 23	$147M	$60M	-$30M
Q3 23	$152M	$62M	-$24M
Q4 23	$156M	$68M	-$19M
Q1 24	$156M	$65M	-$31M
Q2 24	$165M	$72M	-$22M
Q3 24	$168M	$75M	-$21M
Q4 24	$172M	$77M	-$18M
Q1 25	$168M	$73M	-$28M
Q2 25	$181M	$77M	-$48M
Q3 25	$188M	$80M	-$27M
Q4 25	$190M	$76M	-$11M

Valuation

Quarter	P/S	P/E
Q1 22	0.4x	—
Q2 22	0.4x	—
Q3 22	0.4x	—
Q4 22	0.4x	—
Q1 23	0.4x	—
Q2 23	0.4x	—
Q3 23	0.4x	—
Q4 23	0.4x	—
Q1 24	0.4x	—
Q2 24	0.3x	—
Q3 24	0.3x	—
Q4 24	0.3x	—
Q1 25	0.3x	—
Q2 25	0.3x	—
Q3 25	0.3x	—
Q4 25	0.3x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$29M	-$37M
Q2 22	-$17M	-$27M
Q3 22	-$16M	-$24M
Q4 22	-$4M	-$8M
Q1 23	-$13M	-$23M
Q2 23	-$2M	-$9M
Q3 23	-$5M	-$10M
Q4 23	$18M	$11M
Q1 24	-$26M	-$32M
Q2 24	$14M	$814.0K
Q3 24	$9M	-$2M
Q4 24	$10M	-$2M
Q1 25	-$25M	-$30M
Q2 25	$20M	$14M
Q3 25	$9M	$570.0K
Q4 25	$1M	-$7M

Capital Expenditures

Quarter	CapEx
Q1 22	$8M
Q2 22	$10M
Q3 22	$8M
Q4 22	$5M
Q1 23	$10M
Q2 23	$7M
Q3 23	$4M
Q4 23	$7M
Q1 24	$6M
Q2 24	$13M
Q3 24	$11M
Q4 24	$12M
Q1 25	$5M
Q2 25	$6M
Q3 25	$8M
Q4 25	$8M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+1.4%	+29.5%
Q2 22	+2.8%	+14.4%
Q3 22	+6.1%	+4.5%
Q4 22	+10.3%	-1.3%
Q1 23	+17.1%	+1.8%
Q2 23	+17.5%	+7.3%
Q3 23	+18.0%	+4.7%
Q4 23	+12.1%	+5.5%
Q1 24	+13.9%	+8.4%
Q2 24	+12.0%	+5.4%
Q3 24	+10.4%	+7.3%
Q4 24	+10.6%	+9.3%
Q1 25	+7.5%	+4.8%
Q2 25	+10.2%	+22.8%
Q3 25	+11.9%	+13.6%
Q4 25	+10.6%	+5.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$12M	10.3%
Q2 22	$4M	2.9%
Q3 22	$4M	3.3%
Q4 22	$5M	3.4%
Q1 23	$5M	3.5%
Q2 23	$6M	3.9%
Q3 23	$7M	4.7%
Q4 23	$7M	4.5%
Q1 24	$8M	5.0%
Q2 24	$9M	5.4%
Q3 24	$8M	5.0%
Q4 24	$8M	4.8%
Q1 25	$11M	6.4%
Q2 25	$12M	6.7%
Q3 25	$10M	5.5%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	$13M	$60M	$16M
Q2 22	$13M	$56M	$17M
Q3 22	$7M	$64M	$17M
Q4 22	$7M	$55M	$17M
Q1 23	$7M	$62M	$16M
Q2 23	$8M	$60M	$19M
Q3 23	$5M	$61M	$18M
Q4 23	$7M	$60M	$18M
Q1 24	$8M	$66M	$20M
Q2 24	$8M	$63M	$22M
Q3 24	$8M	$67M	$20M
Q4 24	$8M	$64M	$22M
Q1 25	$10M	$68M	$23M
Q2 25	$9M	$72M	$24M
Q3 25	$9M	$70M	$22M
Q4 25	$9M	$64M	$23M

Revenue Segments

Quarter	Clinical Services	Pharma Services
Q1 22	$99M	$18M
Q2 22	$106M	$19M
Q3 22	$106M	$23M
Q4 22	$108M	$31M
Q1 23	$115M	$22M
Q1 24	$135M	$22M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$306M	$176M	$481M
Q2 22	$284M	$182M	$466M
Q3 22	$266M	$177M	$444M
Q4 22	$263M	$175M	$438M
Q1 23	$276M	$142M	$418M
Q2 23	$289M	$120M	$409M
Q3 23	$306M	$96M	$402M
Q4 23	$342M	$73M	$415M
Q1 24	$332M	$53M	$385M
Q2 24	$355M	$33M	$388M
Q3 24	$362M	$26M	$388M
Q4 24	$367M	$20M	$387M
Q1 25	$346M	$12M	$358M
Q2 25	$155M	$9M	$164M
Q3 25	$164M	$0	$164M
Q4 25	$160M	$0	$160M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	25M	+0.4%	+6.4%
Q2 22	25M	+0.4%	-5.5%
Q3 22	25M	+0.3%	+1.5%
Q4 22	25M	+0.2%	+1.3%
Q1 23	25M	+0.3%	+1.1%
Q2 23	25M	+0.3%	+1.0%
Q3 23	25M	+0.3%	+1.0%
Q4 23	25M	+0.2%	+1.0%
Q1 24	25M	+0.1%	+0.9%
Q2 24	25M	+0.2%	+0.8%
Q3 24	25M	+0.4%	+1.0%
Q4 24	25M	-0.2%	+0.6%
Q1 25	25M	+0.6%	+1.0%
Q2 25	26M	+0.4%	+1.2%
Q3 25	26M	-0.0%	+0.8%
Q4 25	26M	+0.6%	+1.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$58.6K	2K
Q2 22	$62.5K	2K
Q3 22	$64.4K	2K
Q4 22	$66.0K	2K
Q1 23	$65.3K	2K
Q2 23	$70.0K	2K
Q3 23	$72.4K	2K
Q4 23	$74.1K	2K
Q1 24	$74.4K	2K
Q2 24	$78.3K	2K
Q3 24	$79.9K	2K
Q4 24	$78.2K	2K
Q1 25	$76.4K	2K
Q2 25	$82.4K	2K
Q3 25	$85.4K	2K
Q4 25	$76.1K	3K

Revenue / Employee